Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients



Status:Withdrawn
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:Any
Updated:4/17/2018
Start Date:January 2012
End Date:January 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
Ceftazidime is a broad spectrum cephalosporin with high activity against a variety of
Gram-negative pathogens, including Pseudomonas aeruginosa. An open-label study of intravenous
ceftazidime pharmacokinetics will be performed in patients undergoing intermittent
hemodialysis at Northwestern Memorial Hospital to determine the clearance of ceftazidime in
high flux hemodialysis.


Inclusion Criteria:

- Eligible patients are male or female adults ≥18 years of age with an expected hospital
stay of at least 48 hours, who have end-stage renal disease and been receiving
intermittent hemodialysis for at least 90 days.

- Eligible patients will additionally have either central or peripheral intravenous
access, and will already be prescribed ceftazidime per their primary providers.

- Written informed consent in a form approved by Northwestern Memorial Hospital,
Northwestern University Institutional Review Board, and Midwestern University
Institutional Review Board will be completed by the patient prior to enrollment.

Exclusion Criteria:

- Patients that only receive one dose of ceftazidime in total

- Patients with potentially altered pharmacokinetic parameters (pregnant patients, burn
patients, and those that are morbidly obese (BMI ≥ 40 kg/m2).

- Not meeting inclusion criteria
We found this trial at
1
site
Northwestern Memorial Hospital
251 E Huron St
Chicago, Illinois 60611
(312) 926-2000
Northwestern Memorial Hospital Northwestern Memorial is an academic medical center hospital where the patient comes...
?
mi
from
Chicago, IL
Click here to add this to my saved trials